CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
70.19
-1.66 (-2.31%)
At close: Jul 20, 2026, 4:00 PM EDT
70.69
+0.50 (0.71%)
Pre-market: Jul 21, 2026, 5:35 AM EDT
CG Oncology Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, CG Oncology stock has a consensus rating of "Strong Buy" and an average price target of $90.29. The average 1-year stock price forecast is 28.64% higher than the current stock price, while the lowest is $80 (+13.98%) and the highest is $108 (+53.87%).
Price Target: $90.29 (+28.64%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 10, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $81 | Buy | Maintains | $81 | +15.40% | Jun 30, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $82 | Buy | Maintains | $82 | +16.83% | Jun 23, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $85 | Buy | Reiterates | $85 | +21.10% | Jun 16, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $83 → $87 | Buy | Maintains | $83 → $87 | +23.95% | May 26, 2026 |
Financial Forecast
Revenue This Year
11.73M
from 4.04M
Increased by 190.44%
Revenue Next Year
90.41M
from 11.73M
Increased by 670.47%
EPS This Year
-2.66
from -2.08
EPS Next Year
-2.78
from -2.66
EPS and Forward PE are based on non-GAAP adjusted numbers.